{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:06:00Z","timestamp":1758413160570,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jss.2021.05.054","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T02:29:39Z","timestamp":1625884179000},"page":"737-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients"],"prefix":"10.1016","volume":"268","author":[{"given":"Stefano","family":"Guadagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-2494","authenticated-orcid":false,"given":"Odysseas","family":"Zoras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giammaria","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-5324","authenticated-orcid":false,"given":"Francesco","family":"Masedu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Lasithiotakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8031-7846","authenticated-orcid":false,"given":"Donatella","family":"Sarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta Rosella","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Reay","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2021.05.054_bib0001","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.3747\/co.27.6523","article-title":"Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline","volume":"27","author":"Wright","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4329\/wjr.v5.i2.25","article-title":"Melanoma metastases in the abdomen and pelvis: frequency and patterns of spread","volume":"5","author":"Trout","year":"2013","journal-title":"World J Radiol"},{"key":"10.1016\/j.jss.2021.05.054_bib0003","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jss.2017.03.066","article-title":"Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis","volume":"215","author":"Guadagni","year":"2017","journal-title":"J Surg Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, Version 2.2019","volume":"17","author":"Coit","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jss.2021.05.054_bib0005","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JOP.18.00063","article-title":"Contemporary approaches to in-transit melanoma","volume":"14","author":"Perone","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.jss.2021.05.054_bib0006","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","article-title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Michielin","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Cancer"},{"unstructured":"Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Sydney: Cancer Council Australia. [Version URL: Available at: https:\/\/wiki.cancer.org.au\/australiawiki\/index.php?oldid=186442 ]. Available from: https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma.","key":"10.1016\/j.jss.2021.05.054_bib0008"},{"key":"10.1016\/j.jss.2021.05.054_bib0009","doi-asserted-by":"crossref","first-page":"578","DOI":"10.21147\/j.issn.1000-9604.2019.04.02","article-title":"Chinese guidelines for diagnosis and treatment of melanoma 2018","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1346-8138.15151","article-title":"Japanese Dermatological Association Guidelines: outlines of guidelines for cutaneous melanoma 2019","volume":"47","author":"Nakamura","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jss.2021.05.054_bib0011","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17512433.2019.1689121","article-title":"Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma","volume":"12","author":"Read","year":"2019","journal-title":"Exp Rev Clin Pharmacol"},{"key":"10.1016\/j.jss.2021.05.054_bib0012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fimmu.2017.00965","article-title":"Mycobacterium bovis Bacillus Calmette\u2013Gu\u00e9rin alters melanoma microenvironment favoring antitumor T cell responses and improving M2 macrophage function","volume":"8","author":"Lardone","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jss.2021.05.054_bib0013","first-page":"127","article-title":"Electrochemotherapy in melanoma patients: a single institution experience","volume":"2","author":"Carac\u00f2","year":"2015","journal-title":"Mel Manag"},{"key":"10.1016\/j.jss.2021.05.054_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PPO.0b013e31824b241a","article-title":"Role of radiation therapy in cutaneous melanoma","volume":"18","author":"Hong","year":"2012","journal-title":"Cancer J"},{"key":"10.1016\/j.jss.2021.05.054_bib0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00008390-200302000-00009","article-title":"Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study","volume":"13","author":"Guadagni","year":"2003","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0016","article-title":"Systemic therapies for unresectable locoregional melanoma: a significant area of need","volume":"6","author":"Tie","year":"2019","journal-title":"Mel Manag"},{"key":"10.1016\/j.jss.2021.05.054_bib0017","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S1470-2045(16)30368-0","article-title":"Are we there yet? Prolonged MAPK inhibition in BRAF V600-mutant melanoma","volume":"17","author":"Khushalani","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0018","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1002\/cncr.28851","article-title":"The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition","volume":"120","author":"Chan","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2021.05.054_bib0019","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topollian","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0020","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jss.2021.05.054_bib0021","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2016.1175430","article-title":"Pembrolizumab for melanoma-safety profile and future trends","volume":"15","author":"Daud","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jss.2021.05.054_bib0022","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2021.05.054_bib0023","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.3390\/ijms18112382","article-title":"Does locoregional chemotherapy still matter in the treatment of advanced pelvic melanoma?","volume":"18","author":"Guadagni","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jss.2021.05.054_bib0024","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/CMR.0000000000000367","article-title":"MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study","volume":"27","author":"Guadagni","year":"2017","journal-title":"Mel Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5306\/wjco.v6.i4.57","article-title":"Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma","volume":"6","author":"Cecchini","year":"2015","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0026","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.jss.2021.05.054_bib0027","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jso.23519","article-title":"Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion","volume":"109","author":"Steinman","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0028","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s13104-017-2738-y","article-title":"Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability","volume":"10","author":"Guadagni","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jss.2021.05.054_bib0029","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/030089160609200506","article-title":"Selected hypoxic stop-flow perfusions: indication and limits","volume":"92","author":"Guadagni","year":"2006","journal-title":"Tumori"},{"key":"10.1016\/j.jss.2021.05.054_bib0030","first-page":"1077","article-title":"Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study","volume":"23","author":"Lasithiotakis","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jss.2021.05.054_bib0031","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of The Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0032","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response valuation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jss.2021.05.054_bib0033","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0034","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0002-9610(01)00841-8","article-title":"Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma","volume":"183","author":"Guadagni","year":"2002","journal-title":"Am J Surg"},{"key":"10.1016\/j.jss.2021.05.054_bib0035","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1245\/s10434-019-07288-w","article-title":"Long-term oncologic outcomes after isolated limb infusion for locoregionally metastatic melanoma: an international multicenter analysis","volume":"26","author":"Miura","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0036","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/bjc.1996.652","article-title":"Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathological, immunohistochemical and electron microscopical study","volume":"74","author":"Nooijen","year":"1996","journal-title":"Br J Cancer"},{"doi-asserted-by":"crossref","unstructured":"Beasley GM, Miura J, Zager JS, Tyler DS, Thompson JF, Kroon HM. Isolated limb infusion for melanoma. In: Balch CM, Thompson JF, Gershenwald JE, Atkins MB, Kirkwood JM, McArthur G, et\u00a0al., editors. Cutaneous Melanoma. 6th edition. Switzerland: Springer Nature AG; 2020; pp. 827-50.","key":"10.1016\/j.jss.2021.05.054_bib0037","DOI":"10.1007\/978-3-030-05070-2_27"},{"key":"10.1016\/j.jss.2021.05.054_bib0038","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2010.32.1224","article-title":"Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma","volume":"29","author":"Beasley","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2021.05.054_bib0039","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13569-016-0049-z","article-title":"Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma","volume":"6","author":"Vo","year":"2016","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/02656730701816410","article-title":"Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI","volume":"24","author":"Padussis","year":"2008","journal-title":"Int J Hyperthermia"},{"key":"10.1016\/j.jss.2021.05.054_bib0041","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13104-020-05021-5","article-title":"Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study","volume":"13","author":"Guadagni","year":"2020","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jss.2021.05.054_bib0042","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","article-title":"Robust antitumor responses result from local chemotherapy and CTLA-4 blockade","volume":"6","author":"Ariyan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0043","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s13046-019-1425-3","article-title":"A pilot study of alternative TrkAIII splicing in Merkel cell carcinoma: A potential oncogenic mechanism and novel therapeutic target","volume":"38","author":"Cappabianca","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jss.2021.05.054_bib0044","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/CMR.0000000000000719","article-title":"The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials","volume":"31","author":"Bagge","year":"2021","journal-title":"Mel Res"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480421003814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480421003814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:00:41Z","timestamp":1758380441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480421003814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":44,"alternative-id":["S0022480421003814"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2021.05.054","relation":{},"ISSN":["0022-4804"],"issn-type":[{"type":"print","value":"0022-4804"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2021.05.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}